Pharma's global karma: Focus on Novartis, Pfizer and Ranbaxy

Abstract

Purpose of this paper

Reviews the latest management developments across the globe and pinpoints practical implications from cutting‐edge research and case studies.

Design/methodology/approach

This briefing is prepared by an independent writer who adds their own impartial comments and places the articles in context.

Findings

The major players within the pharmaceutical industry have long positioned themselves as global players. The economics behind it have been simple. The cost of drug discovery is immense and uncertain. The widest possible global sales are needed to recoup the investment, reinvest in the next generation of research and development, and make a decent profit.

Practical implications

Provides strategic insights and practical thinking that have influenced some of the world's leading organizations.

Originality/value

The briefing saves busy executives and researchers hours of reading time by selecting only the very best, most pertinent information and presenting it in a condensed and easy‐to‐digest format.

Citation

(2006), "Pharma's global karma: Focus on Novartis, Pfizer and Ranbaxy", Strategic Direction, Vol. 22 No. 1, pp. 5-8. https://doi.org/10.1108/02580540610635852